learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Proteolysis-Targeting Chimera (PROTAC): Current Applications And Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Proteolysis-Targeting Chimeras in Cancer Therapy: Targeted Protein Degradation for Next-Generation Treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Protacs: A Novel Strategy For Cancer Drug Discovery And Development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
Community Join
5 / 70 resultscommunity More great news about SCUBE3... this could be it!
SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.
community bro where tf is GT20029, Q1 2024 is over already
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Grey Market GT20029 and Frequency of Application
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.